146948-68-7

Basic information

• Product Name: 2-BROMO-4-CHLORO-6-METHYLANILINE
• Synonyms: 2-BROMO-4-CHLORO-6-METHYLANILINE;2-Bromo-4-chloro-6-methyl-phenylamine
• CAS NO: 146948-68-7
• Molecular Formula: C₇H₇BrClN
• Molecular Weight: 220.49
• Product Categories: Anilines, Amides & Amines;Bromine Compounds;Chlorine Compounds
• Mol File: 146948-68-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 46-48°C
• Boiling Point: 282.9°C at 760 mmHg
• Flash Point: 124.9°C
• Appearance: /
• Density: 1.619g/cm³
• Vapor Pressure: 0.00326mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 1.75±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-4-CHLORO-6-METHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-CHLORO-6-METHYLANILINE(146948-68-7)
• EPA Substance Registry System: 2-BROMO-4-CHLORO-6-METHYLANILINE(146948-68-7)

Safety Data

• Hazardous Substances Data: 146948-68-7(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-chloro-6-methylaniline is a chemical compound with the molecular formula C7H7BrClN. It is a derivative of aniline, with bromine, chlorine, and a methyl group attached to the benzene ring. 2-BROMO-4-CHLORO-6-METHYLANILINE is commonly used as an intermediate in the synthesis of various pharmaceuticals, dyes, and agrochemicals. It is also utilized in the manufacturing of organic compounds and as a building block in organic chemistry. 2-Bromo-4-chloro-6-methylaniline has a reddish-brown appearance and is considered to be a toxic substance when ingested, inhaled, or in contact with the skin, and should be handled with caution in a controlled laboratory setting.

InChI:InChI=1/C7H7BrClN/c1-4-2-5(9)3-6(8)7(4)10/h2-3H,10H2,1H3

Upstream product

• 95-69-2 4-chloro-2-methylbenzeneamine 
• 615-65-6 2-chloro-4-methyl-benzenamine 
• 329944-72-1 1-bromo-3-chloro-5-methylbenzene 
• 30273-42-8 2-methyl-4-bromo-6-chloroaniline 
• 24106-05-6 4'-bromo-2'-methylacetanilide 
• 7647-01-0 hydrogenchloride 
• 866998-75-6 3-bromo-5-chloro-2-nitro-toluene 

Downstream Products

• 329944-72-1 1-bromo-3-chloro-5-methylbenzene 
• 70630-20-5 2-[(2-Bromo-4-chloro-6-methyl-phenyl)-(2-methoxy-acetyl)-amino]-propionic acid methyl ester 
• 70630-21-6 2-[(2-Bromo-4-chloro-6-methyl-phenyl)-(2-ethoxy-acetyl)-amino]-propionic acid methyl ester 
• 500008-45-7 rynaxypyr 
• 1391132-23-2 2-hydroxyethyl 2-amino-5-chloro-3-methylbenzoate 
• 1391132-24-3 2-(dimethylamino)ethyl 2-amino-5-chloro-3-methylbenzoate 
• 890707-28-5 2-amino-3-methyl-5-chlorobenzoyl-N-methylamine 
• 939990-03-1 2-amino-5-chloro-3-methylbenzonitrile 
• 644961-69-3 4-chloro-2-methoxy-6-methylphenylamine 
• 84388-49-8 3-bromo-5-chloro-2,4,6-trinitro-toluene 

Relevant articles and documents

Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors

Genome-wide-association studies in chronic low back pain patients identified sepiapterin reductase as a high interest target for developing new analgesics. Here we used 19F NMR fragment screening for the discovery of novel, ligand-efficient SPR

Discovery of a 7-arylaminobenzimidazole series as novel CRF1receptor antagonists

A promising lead compound 1 of a benzimidazole series has been identified as a corticotropin-releasing factor 1 (CRF1) receptor antagonist. In this study, we focused on replacement of a 7-alkylamino group of 1, predicted to occupy a large lipophilic pocket of a CRF1receptor, with an aryl group. During the course of this examination, we established new synthetic approaches to 2,7-diarylaminobenzimidazoles. The novel synthesis of 7-arylaminobenzimidazoles culminated in the identification of compounds exhibiting inhibitory activities comparable to the alkyl analog 1. A representative compound, p-methoxyanilino analog 16g, showed potent CRF binding inhibitory activity against a human CRF1receptor and human CRF1receptor antagonistic activity (IC50?=?27?nM, 56?nM, respectively). This compound exhibited ex vivo125I-Tyr0(125I-CRF) binding inhibitory activity in mouse frontal cortex, olfactory bulb, and pituitary gland at 20?mg/kg after oral administration. In this report, we discuss the structure–activity-relationship of these 7-arylamino-1H-benzimidazoles and their synthetic method.

BENZIMIDAZOLE COMPOUNDS

There is provided a compound of the formula (1) wherein R1 is an optionally substituted C1-10 alkyl; R2 is H, or a C1-6 alkyl which may be substituted with 1 to 3 substituents; R3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6- membered ring which may be substituted with 1 to 3 C1-6 alkyls; R4 is a hydrogen, a halogen, a hydroxy, a cyano, a C1-6 alkyl or a C1-6 alkoxy; Z is -O-, -S-, -SO-, -SO2-, or - NR5- wherein R5 is a hydrogen or a C1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.